Biogen price target lowered to $180 from $190 at Barclays

Barclays lowered the firm’s price target on Biogen (BIIB) to $180 from $190 and keeps an Equal Weight rating on the shares post the Q3 report. The company’s launches are “still challenged” with increasing competitive noise, while its emerging pipeline catalysts remain weighted to 2026 and beyond, the analyst tells investors in a research note.